Standard BioTools (LAB) Expected to Announce Quarterly Earnings on Tuesday

Standard BioTools (NASDAQ:LAB) is projected to post its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Standard BioTools to post earnings of ($0.03) per share and revenue of $18.50 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:00 PM ET.

Standard BioTools Price Performance

Shares of NASDAQ LAB opened at $1.12 on Tuesday. Standard BioTools has a 1 year low of $0.92 and a 1 year high of $1.72. The stock has a market cap of $430.72 million, a PE ratio of -3.29 and a beta of 1.29. The firm has a fifty day moving average price of $1.42 and a 200-day moving average price of $1.34.

Insiders Place Their Bets

In other Standard BioTools news, Director Casdin Partners Master Fund, L bought 150,000 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were acquired at an average price of $1.45 per share, with a total value of $217,500.00. Following the transaction, the director owned 72,100,000 shares of the company’s stock, valued at approximately $104,545,000. This trade represents a 0.21% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders acquired 8,850,000 shares of company stock worth $11,565,500. Insiders own 23.16% of the company’s stock.

Institutional Investors Weigh In On Standard BioTools

Several institutional investors have recently added to or reduced their stakes in the business. Kent Lake PR LLC acquired a new stake in shares of Standard BioTools during the second quarter worth $1,200,000. Landscape Capital Management L.L.C. purchased a new position in Standard BioTools in the 4th quarter worth $792,000. AQR Capital Management LLC grew its stake in Standard BioTools by 862.2% during the 1st quarter. AQR Capital Management LLC now owns 482,912 shares of the company’s stock valued at $522,000 after purchasing an additional 432,725 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Standard BioTools by 1.6% in the third quarter. Vanguard Group Inc. now owns 17,245,583 shares of the company’s stock worth $22,419,000 after purchasing an additional 263,845 shares during the last quarter. Finally, Front Street Capital Management Inc. acquired a new stake in shares of Standard BioTools during the second quarter worth about $145,000. Institutional investors and hedge funds own 53.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Standard BioTools in a report on Thursday, January 22nd. Wall Street Zen downgraded Standard BioTools from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 8th. Zacks Research raised shares of Standard BioTools to a “hold” rating in a report on Thursday, December 11th. Finally, TD Cowen decreased their price target on shares of Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a research note on Wednesday, November 5th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Standard BioTools presently has a consensus rating of “Reduce” and a consensus price target of $1.35.

About Standard BioTools

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.